Physician profile
Devyn Morin
NPI 1932874443
$1,290.24
in general payments reported to CMS, 2019-2025
11 companies · $838 in 2025
The $838 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $17.46 · 2023: $110 · 2024: $27.91 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.89 | 2021-2025 | |
| Indivior INC. | $289.99 | 2025 | Sublocade |
| Alkermes, INC. | $221.04 | 2025 | Vivitrol, Aristada, Lybalvi |
| Amgen INC. | $142.09 | 2021 | |
| Lundbeck LLC | $77.93 | 2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $69.43 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Braeburn INC. | $69.28 | 2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $53.90 | 2025 | Spravato |
| Lilly USA, LLC | $26.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2025 | Uzedy |
| Orexo US, INC. | $13.58 | 2025 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devyn Morin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.